Range Low Price High Price Comment
30 days $10.69 $17.49 Tuesday, 30th Apr 2024 CRIS stock ended at $15.35. This is 4.35% more than the trading day before Monday, 29th Apr 2024. During the day the stock fluctuated 5.43% from a day low at $14.56 to a day high of $15.35.
90 days $8.24 $17.49
52 weeks $0.380 $17.49

Historical Curis prices

Date Open High Low Close Volume
Feb 02, 2016 $1.67 $1.68 $1.57 $1.59 317 800
Feb 01, 2016 $1.63 $1.75 $1.61 $1.67 369 700
Jan 29, 2016 $1.61 $1.73 $1.55 $1.64 465 600
Jan 28, 2016 $1.73 $1.76 $1.61 $1.61 439 100
Jan 27, 2016 $1.80 $1.84 $1.70 $1.70 250 300
Jan 26, 2016 $1.85 $1.95 $1.70 $1.80 248 100
Jan 25, 2016 $1.81 $1.90 $1.79 $1.81 239 300
Jan 22, 2016 $1.87 $1.94 $1.76 $1.80 632 900
Jan 21, 2016 $1.82 $1.92 $1.72 $1.82 305 100
Jan 20, 2016 $1.74 $1.92 $1.62 $1.86 504 800
Jan 19, 2016 $1.97 $1.98 $1.73 $1.76 261 700
Jan 15, 2016 $1.86 $1.89 $1.67 $1.88 416 900
Jan 14, 2016 $1.96 $2.02 $1.60 $1.93 653 700
Jan 13, 2016 $2.15 $2.21 $1.90 $1.91 346 400
Jan 12, 2016 $2.14 $2.26 $2.00 $2.13 314 600
Jan 11, 2016 $2.21 $2.25 $1.96 $2.11 512 100
Jan 08, 2016 $2.38 $2.43 $2.15 $2.21 359 400
Jan 07, 2016 $2.53 $2.56 $2.30 $2.36 422 500
Jan 06, 2016 $2.70 $2.74 $2.52 $2.59 361 300
Jan 05, 2016 $2.78 $2.80 $2.70 $2.75 218 200
Click to get the best stock tips daily for free!

About Curis

Curis Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize t... CRIS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT